Pseudomonas Exotoxin-based Immunotoxins Containing the Antibody LL2 or LL2-Fab' Induce Regression of Subcutaneous Human B-Cell Lymphoma in Mice

Cancer Research

Volumn 53, Issue 4, 1993, Pages 819-825

  Goldenberg, David M ^c   Jones, Anastasia L ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TOXIN ANALYSIS;

ANIMAL; ANTIBODIES, MONOCLONAL; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; EXOTOXINS; FEMALE; HUMAN; IMMUNOGLOBULINS, FAB; IMMUNOTOXINS; LYMPHOMA, B-CELL; MICE; MICE, NUDE; SKIN NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; WHOLE-BODY IRRADIATION;

EID: 0027407178     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Devesa, S. S. Silverman, D. T. Young, J. L. Jr. Pollack, E. S. Brown, C. C. Horm, J. W. Percy, C. L. Myers, M. H. McKay, F. W. and Fraumeni, J. F. Jr. Cancer incidence and mortality trends among whites in the United States, 1947-84. J. Natl. Cancer Inst. 79: 701-770, 1987.
2. Foon, K. A. Rai, K. R. and Gale, R. P. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intern. Med. 113: 525-539, 1990.
3. Vitetta, E. S. Fulton, R. J. May, R. D. Till, M. and Uhr, J. W. Redesigning nature's poisons to create anti-tumor reagents. Science (Washington DC), 238: 1098-1104, 1987.
4. Shen, G. Li, J. Ghetie, M. Ghetie, V. May, R. D. Till, M. Brown, A. N. Relf, M. Knowles, P. Uhr, J. W. Janossy, G. Amlot, P. Vitetta, E. S. and Thorpe, P. E. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int. J. Cancer, 42: 792-797, 1988.
5. Ghetie, M. May, R. D. Till, M. Uhr, J. W. Ghetie, V. Knowles, P. P. Relf, M. Brown, A. Wallace, P. M. Janossy, G. Amlot, P. Vitetta, E. S. and Thorpe, P. E. Evaluation of ricin A chain-containing immunotoxins directed against CD 19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 48: 2610-2617, 1988.
6. Ghetie, M. Richardson, J. Tucker, T. Jones, D. Uhr, J. W. and Vitetta, E. S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer, 45: 481-485, 1990.
7. Ghctie, M. Richardson, J. Ticker, T. Jones, D, Uhr, J. W. and Vitetta, E. S. Antitumor activity of Fab’ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 51: 5876-5880, 1991.
8. Vitetta, E. S. Stone, M. Amlot, P. Fay, J. May, R. Till, M. Newman, J. Clark, P. Collins, R. Cunningham, D. Ghetie, V. Uhr, J. W. and Thorpe, P. E. Phase I immunotoxin tRIal in patients with B-cell lymphoma. Cancer Res. 57: 4052-4058, 1991.
9. Lambert, J. M. Goldmacher, V. S. Collison, A. R. Nadler, L. M. and Blattler, W. A. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res. 51: 6236-6242, 1991.
10. Grossbard, M. L. Freedman, A. S. Ritz, J. Coral, F. Goldmacher, V. S. Eliseo, L. Spector, N. Dear, K. Lambert, J. M. Blattler, W. A. Taylor, J. A. and Nadler, L. M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I tRIal of daily bolus infusion. Blood, 79: 576-585, 1992.
11. Uckun, F. M. Anti-CD 19 immunotoxins for in vivo immunotherapy of B-lineage acute lymphoblastic leukemias. Antibody Immunoconj. Radiopharm. 1. 247-262, 1988.
12. Jansen, B. Uckun, F. M. Jaszcz, W. B. and Kersey, J. H. Establishment of a human t(4; 11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD 19 (B43)-pokeweed antiviral protein immunotoxin. Cancer Res. 52: 406-12, 1992.
13. Pawlak-Byczkowska, E. J. Hansen, H. J. Dion, A. S. and Goldenberg, D. M. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res. 49: 4568-4577, 1989.
14. Lu, H. H. Shih, L. B. Xuan, H. and Goldenberg, D. M. Internalization and cellular distribution of an anti-B-cell lymphoma antibody, LL2. Proc. Am. Assoc. Cancer Res. 33: 342, 1992.
15. Goldenberg, D. M. Horowitz, J. A. Sharkey, R. M. Hall, T. C. Murthy, S. Goldenberg, H. Lee, R. E. Stein, R. Siegel, J. A. Izon, D. O. Burger, K. Swayne, L. C. Belisle, E. Hansen, H. J. and Pinsky, C. M. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol. 9: 548-564, 1991.
16. Chaudhary, V. K. Queen, C. Junghans, R. P. Waldmann, T. A. FitzGerald, D. J. and Pastan, I. A. recombinant immunotoxin consisting of two antibody vaRIable domains fused to Pseudomonas exotoxin. Nature (Lond.), 339: 394-397, 1989.
17. Ogata, M. Chaudhary, V. K. Pastan, I. and FitzGerald, D. J. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J. Biol. Chem. 265: 20678-20685, 1990.
18. Allured, V. S. Collier, R. J. Carroll, S. F. and McKay, D. B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc. Natl. Acad. Sci. USA, 83: 1320-1324, 1986.
19. Hwang, J. FitzGerald, D. J. Adhya, S. and Pastan, I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Ce\\,48: 129-136, 1987.
20. Siegall, C. B. Chaudhary, V. K. FitzGerald, D. J. and Pastan, I. Functional analysis of domains 11, lb, and III of Pseudomonas exotoxin. J. Biol. Chem. 264: 14256-14261, 1989.
21. Chaudhary, V. K. Jinno, Y. FitzGerald, D. J. and Pastan, I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc. Natl. Acad. Sci. USA, 87: 308-312, 1990.
22. Seetharam, S. Chaudhary, V. K. FitzGerald, D. J. and Pastan, I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. 266: 17376-17381, 1991.
23. Kondo, T. FitzGerald, D. Chaudhary, V. K. Adhya, S. and Pastan, I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J. Biol. Chem. 263: 9470-9475, 1988.
24. Batra, J. K. Jinno, Y. Chaudhary, V. K. Kondo, T. Willingham, M. C. FitzGerald, D. J. and Pastan, I. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 86: 8545-8549, 1989.
25. Pai, L. H. Batra, J. K. FitzGerald, D. J. Willingham, M. C. and Pastan, I. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 88: 3358-3362, 1991.
26. Gold, D. V. Nocera, M. A. Stephens, R. and Goldenberg, D. M. Murine monoclonal antibodies to colon-specific antigen p. Cancer Res. 50: 6405-6409, 1990.
27. Collier, R. J. and Kandell, J. Structure and activity of diphtheRIa toxin. I. Thioldependent dissociation of a fraction of toxin into enzymatically active and inactive fragments. J. Biol. Chem. 246: 1496-1503, 1971.
28. Ghetie, M. Tucker, K. Richardson, J. Uhr, J. W. and Vitetta, E. S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD 19 antibody or an anti-CD 19 immunotoxin. Blood, 80: 2315-2320, 1992.
29. Uckun, F. M. Manivel, C. Arthur, D. Chelstrom, L. M. Finnegan, D. Tuel-Ahlgren, L. Irvin, J. D. Myers, D. E. and Gunther, R. In vivo efficacy of B43 (anti-CD 19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood, 79: 2201-2214, 1992.
30. Larson, L. N. Johansson, C. Lindholm, L. and Homgren, J. Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells. Int. J. Cancer, 42: 877-882, 1988.